Sudarshan Pharma Industries Ltd (SUDARSHAN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sudarshan Pharma Industries Ltd on NSE and BSE, with an AI summary of each filing.
In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising ....
Others (Uncategorized) · 31 Oct 2026, 1:58 am
Sudarshan Pharma Board Approves ₹72 Crore Convertible Warrants Issue to Promoters Sudarshan Pharma Industries' Board approved raising up to ₹72 crore via the preferential issue and allotment of convertible warrants to promoters Mr. Hemal Mehta and Mr. Sachin Mehta on 29th Oct'26. Each warrant is convertible into one equity share of face value Re 1. The issue price will be determined under Regulation 164 of SEBI ICDR Regulations. The fundraise remains subject to regulatory and shareholder approvals at an upcoming Extraordinary General Meeting.
This is to inform you that the Board of Directors of the Company at its Board Meeting held on 29/Oct/2026 has approved the proposal to raising funds through issue and allotment of up to ....
Others (Uncategorized) · 30 Oct 2026, 8:35 pm
Sudarshan Pharma Board Approves Issuance of 72 Crore Convertible Warrants to Promoters Sudarshan Pharma Industries' board approved raising funds via the preferential issuance and allotment of up to 72 crore convertible warrants to promoters Hemal Mehta and Sachin Mehta on 29th Oct'26. Each warrant is convertible into one equity share of face value Re 1. The issue price will be determined in accordance with SEBI ICDR Regulations. The transaction remains subject to statutory, regulatory, and shareholder approvals at an upcoming Extraordinary General Meeting.
We are submitting herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026
Financial Result · 30 Oct 2026, 4:04 am
We are submitting the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026
Financial Result · 30 Oct 2026, 3:56 am
Sudarshan Pharma Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 21,697 (+28.5% YoY | +24.4% QoQ) ■ EBITDA: 2,058 (+123.6% YoY | +29.4% QoQ) ■ EBITDA Margin (%): 9.5 (+404 bps YoY | +37 bps QoQ) ■ PAT: 809 (+93.3% YoY | +38.1% QoQ) ■ EPS (INR): 0.31 (+93.8% YoY | +34.8% QoQ)
Sudarshan Pharma Industries Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Fund raising.
Intimation · 29 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and Fund Raising
Intimation · 29 Oct 2026, 5:30 am
Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve i) Unaudited Standalone ....
Intimation · 29 Oct 2026, 5:30 am
Sudarshan Pharma Board to Consider Q2 Results and Fund Raising Sudarshan Pharma Industries' Board of Directors is scheduled to meet on 29th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The board will also evaluate a proposal for fund raising via equity shares, convertible securities, warrants, or debt instruments through private placement, preferential issue, Qualified Institutions Placement (QIP), or other modes, subject to regulatory approvals. The company's trading window remains closed until 48 hours post the result declaration.
We are pleased to inform you that the Company ahs received letter from National Stock Exchange of India Limited dated 23-Oct-2026 stating that the equity shares of the Company shall be ....
Others (Uncategorized) · 23 Oct 2026, 11:55 pm
Sudarshan Pharma Migrates to NSE Main Board Effective 27th Oct'26 Sudarshan Pharma Industries has received approval from the National Stock Exchange of India (NSE) to list its equity shares on the Main Board (Capital Market Segment), effective 27th Oct'26, migrating from the BSE SME platform. A total of 254,470,600 fully paid-up equity shares of Re. 1/- each will trade under the symbol SUDARSHAN in the EQ series with a market lot of one share. Of the total equity capital, 117,244,110 shares are free from lock-in, while the remaining shares are locked in until Dec'27 and Feb'28.
In continuation of the Company''s letters dated 05/Sep/2026 and 15/Sep/2026, this is to inform you that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology ....
Others (Uncategorized) · 07 Oct 2026, 8:05 pm
Sudarshan Pharma Terminates Acquisition of Med Therapy Biotechnology Common Stock Sudarshan Pharma Industries announced on 7th Oct'26 that its proposal to acquire a 9.50% equity stake in USA-based Med Therapy Biotechnology Inc. has been terminated. Concurrently, the proposals for promoters Hemal Mehta (Chairman & Managing Director) and Sachin Mehta (Joint Managing Director) to acquire a 1.50% equity stake each in Med Therapy Biotechnology have also been terminated.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in conitinuation of the Company''s letter dated 13/Aug/2026 regarding stake sale ....
Others (Uncategorized) · 28 Sept 2026, 11:08 pm
Sudarshan Pharma Completes Divestment of 51% Stake in Ishwari Healthcare Sudarshan Pharma Industries Ltd completed the sale of its entire 51.00% equity stake in subsidiary Ishwari Healthcare Private Limited on 28th Sep'26. The transaction comprised 2,09,100 equity shares (face value Rs. 10 each) sold to Mr. Amit Jatin Mehta for an aggregate consideration of Rs. 1.40 Crores. Following the divestment, Sudarshan Pharma's shareholding in Ishwari Healthcare has been reduced to nil, and Ishwari Healthcare has ceased to be a subsidiary of the company.
Please find enclosed the Scrutinizer''s Report on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 through video conferencing / other ....
Annual General Meeting · 23 Sept 2026, 12:36 am
Please find enclosed the voting results on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 at 3:00 p.m. through Video Conferencing/ ....
Annual General Meeting · 23 Sept 2026, 12:25 am
Pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations, 2015 we enclose herewith the summary of proceedings of the AGM.
Annual General Meeting · 22 Sept 2026, 10:21 pm
Pursuant to Reg 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of the Company letter no. SPIL/CS/2026-2027/57 dated 5th September 2026, ....
Others (Uncategorized) · 15 Sept 2026, 7:43 pm
Sudarshan Pharma Updates on Proposed Stake Acquisition in Med Therapy Biotechnology Sudarshan Pharma Industries announced that its proposal to acquire a 9.50% equity stake in USA-based Med Therapy Biotechnology Inc. remains under due diligence, pending board resolutions and final confirmation from Med Therapy's Board of Directors. Concurrently, proposals for company promoters Hemal Mehta (CMD) and Sachin Mehta (Joint MD) to acquire a 1.50% equity stake each are also undergoing due diligence and awaiting board approval. The company stated these were preliminary intimations and further updates will be disclosed once progress is finalized.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal V ....
Encumbered Shares - Invocation / Release · 10 Sept 2026, 1:29 am
Sudarshan Pharma Industries Promoters Pledge Equity Shares for Corporate Loan Security Sudarshan Pharma Industries disclosed promoter group share encumbrances created on 13th Aug'26 in favor of Gangabase Barter Private Limited as collateral for a company loan. Devangi Hemal Mehta pledged 22,94,000 shares (0.95% stake), while Hemal V Mehta HUF and Namrata Sachin Mehta each pledged 16,45,000 shares (0.68% stake each). Additionally, Sachin V Mehta HUF pledged 14,78,147 shares (0.61% stake). The revised disclosures were submitted under SEBI SAST Regulations on 9th Sep'26 following prior exchange correspondence.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal Vasantrai Mehta
Encumbered Shares - Invocation / Release · 10 Sept 2026, 1:27 am
Sudarshan Pharma Promoter Releases Entire Pledged Stake Sudarshan Pharma Industries Limited disclosed that promoter Mr. Hemal Vasantrai Mehta released a pledge on 20,00,000 equity shares (0.83% of total share capital) on 6th Aug'26. The pledge, originally created in favor of Mr. Kirit Ratilal Shah for personal loan requirements, leaves the promoter with zero encumbered shares post-transaction. Mr. Mehta continues to hold 64,01,020 equity shares, representing 26.60% of the company's total share capital.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directros have at their Meeting held today, ....
Others (Uncategorized) · 06 Sept 2026, 1:04 am
Sudarshan Pharma Board Approves 9.50% Stake Acquisition in MedTherapy Biotechnology Sudarshan Pharma Industries approved acquiring 24,23,675.64 equity shares (9.50% stake) of US-based MedTherapy Biotechnology Inc. via an all-cash transaction in USD, expected to close by 31st Mar'27. Additionally, promoters Hemal Mehta and Sachin Mehta will acquire 1.50% each (3,82,685.63 shares each). MedTherapy Biotech is a Boston-based CAR-T cell CDMO with manufacturing in New Delhi and R&D in Boston. The acquisition enables Sudarshan Pharma to establish a US footprint, access distribution networks, and broaden into cell and gene therapy offerings.
Pursuant to Reg 34 of SEBI Listing Regulations, please find enclosed the Annual Report of the Company for the FY 2025-26.
Others (Uncategorized) · 29 Aug 2026, 8:19 pm
Pursuant to Reg 34 of SEBI Listing Regulations, please find enclosed the Annual Report of the Company for the FY 2025-26.
Others (Uncategorized) · 29 Aug 2026, 8:17 pm
Pursuant to Regulation 34 of SEBI Listing Regulations, please find enclosed the Notice of 18th Annual General Meeting to be held on Tuesday, 22/September/2026.
Annual General Meeting · 29 Aug 2026, 8:01 pm
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 26, 2026 for Hemal V Mehta & Sachin V Mehta
Encumbered Shares - Invocation / Release · 27 Aug 2026, 1:01 am
Sudarshan Pharma Promoters Pledge Shares Promoters Hemal V. Mehta and Sachin V. Mehta have created a new pledge on their equity shares. On Aug 25, '26, Hemal V. Mehta pledged 66.5M shares (2.61% of total capital), bringing his total encumbered shares to 132.5M (5.21%). On the same day, Sachin V. Mehta also pledged 66.5M shares (2.61%), increasing his total pledged shares to 132.5M (5.21%). Both pledges were made as security for a loan taken by a third party and are in favor of Satin Finserv Limited.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 21, 2026 for Hemal V Mehta & Sachin V Mehta
Encumbered Shares - Invocation / Release · 22 Aug 2026, 3:43 pm
Sudarshan Pharma Promoters Pledge Shares as Loan Collateral Promoters Hemal V Mehta and Sachin V Mehta have created a new pledge on their shares in Sudarshan Pharma Industries. On 20 Aug'26, each promoter pledged 6.6mn shares (2.64% stake each), totaling 13.2mn shares or a 5.28% stake. The shares were pledged in favor of Satin Finserv Limited as security for a loan taken by the company itself. Post-event, the total encumbered promoter holding for each individual is now 6.6mn shares, representing 2.64% of the total share capital for each promoter.
It is hereby informed that the members of the FCCB COmmittee of the COmpany, have at their meeting held today, 19/Aug/2026, have approved allotment of 48,11,730 fully paid-up equity shares ....
Others (Uncategorized) · 20 Aug 2026, 12:14 am
Sudarshan Pharma Allots Shares on Conversion of FCCBs Sudarshan Pharma Industries has allotted 48,11,730 equity shares of Re.1/- each on 19th Aug'26, following the conversion of Foreign Currency Convertible Bonds (FCCBs) worth USD 15.0M. The shares were issued at a price of Rs.30.19 per share, including a premium of Rs.29.19. Post-allotment, the company's total number of shares increased to 25,44,70,600, raising its issued and paid-up capital to Rs. 25.45 crore. The new shares will rank pari-passu with existing equity shares.
Pursuant to Regulation 30 of SEBI LODR Regulations, We hereby submit the updated Investor Presentation
Investor Presentation · 18 Aug 2026, 6:09 pm
Sudarshan Pharma Q1FY27 Results and Growth Outlook Sudarshan Pharma Industries reported Q1FY27 (unaudited) revenue of Rs 174.41 Cr and PAT of Rs 5.61 Cr. PAT margin stood at 3.21%. For FY26, revenue is projected at Rs 703.06 Cr (+39.2% YoY) with PAT at Rs 23.30 Cr (+46.7% YoY). The company aims to capitalize on the "China+1" strategy by focusing on vertical integration from intermediates to branded generics. Key growth drivers include acquisitions, capacity expansion in Palghar, a new GMP-certified API unit in Hyderabad, and aggressive export targets of Rs 100 Cr for FY27.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Vasantrai Ratilal ....
Encumbered Shares - Invocation / Release · 17 Aug 2026, 1:53 pm
Sudarshan Pharma Promoters Pledge Shares as Loan Security Sudarshan Pharma Industries' promoter group entities have created a share pledge on 13th Aug'26. A total of 66,20,137 shares, representing 2.74% of total share capital, were pledged in favor of Gangabase Barter Private Limited. The pledge acts as security for a loan taken by the company. Entities involved include Vasantrai Mehta, Jatin Mehta, Hemal V Mehta HUF, Devangi Mehta, Sachin V Mehta HUF, and Namrata Mehta. Prior to this event, these promoter group entities held nil encumbered shares.